- Home
- SNSE vs BIOR Comparison
SNSE vs BIOR Comparison
Compare SNSE & BIOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNSE
- BIOR
- Stock Information
- Founded
- SNSE 2005
- BIOR 2010
- Country
- SNSE United States
- BIOR United States
- Employees
- SNSE N/A
- BIOR N/A
- Industry
- SNSE Biotechnology: Pharmaceutical Preparations
- BIOR Biotechnology: Pharmaceutical Preparations
- Sector
- SNSE Health Care
- BIOR Health Care
- Exchange
- SNSE Nasdaq
- BIOR Nasdaq
- Market Cap
- SNSE 12.3M
- BIOR 12.6M
- IPO Year
- SNSE 2021
- BIOR 2020
- Fundamental
- Price
- SNSE $0.46
- BIOR $2.34
- Analyst Decision
- SNSE Strong Buy
- BIOR Strong Buy
- Analyst Count
- SNSE 3
- BIOR 1
- Target Price
- SNSE $4.33
- BIOR $150.00
- AVG Volume (30 Days)
- SNSE 894.4K
- BIOR 126.0K
- Earning Date
- SNSE 11-14-2024
- BIOR 11-14-2024
- Dividend Yield
- SNSE N/A
- BIOR N/A
- EPS Growth
- SNSE N/A
- BIOR N/A
- EPS
- SNSE N/A
- BIOR N/A
- Revenue
- SNSE N/A
- BIOR $860,000.00
- Revenue This Year
- SNSE N/A
- BIOR $32,550.00
- Revenue Next Year
- SNSE N/A
- BIOR $95.48
- P/E Ratio
- SNSE N/A
- BIOR N/A
- Revenue Growth
- SNSE N/A
- BIOR 777.55
- 52 Week Low
- SNSE $0.38
- BIOR $2.30
- 52 Week High
- SNSE $1.94
- BIOR $19.90
- Technical
- Relative Strength Index (RSI)
- SNSE 43.28
- BIOR 28.61
- Support Level
- SNSE $0.52
- BIOR $2.42
- Resistance Level
- SNSE $0.59
- BIOR $3.10
- Average True Range (ATR)
- SNSE 0.05
- BIOR 0.34
- MACD
- SNSE -0.01
- BIOR -0.02
- Stochastic Oscillator
- SNSE 8.72
- BIOR 3.43
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing highly selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101, SNS-102, SNS-103, SNS-20.
About BIOR Biora Therapeutics Inc.
Biora Therapeutics Inc is a biotechnology company engaged in developing oral biotherapeutics. Its drug-device combinations could enable new treatment approaches in the delivery of therapeutics in two main areas: Targeted delivery of therapeutics to the site of disease in the gastrointestinal ("GI") tract, which is designed to improve outcomes for patients with Inflammatory Bowel Disease (IBD); and Systemic delivery of biotherapeutics, which are designed to replace injection with needle-free, oral delivery technology.